Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Galactokinase deficiency is a rare mild form of galactosemia characterized by early onset of cataract and an absence of the usual signs of classic galactosemia, i.e. feeding difficulties, poor weight gain and growth, lethargy, and jaundice.
Features include always present findings: Reduced erythrocyte galactokinase activity; and sometimes findings: Increased intracranial pressure. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Cataract |
Digestive system |
GALK1 encodes galactokinase 1 (392 aa). Catalyzes the transfer of a phosphate from ATP to alpha-D-galactose and participates in the first committed step in the catabolism of galactose Highest expression in Liver (40.1 TPM) and Nerve Tibial (31.2 TPM).
Galactokinase deficiency is caused by mutations in the GALK1 gene on chromosome 17.
The GALK1 protein participates in GALM converts beta-D-GAL to alpha-D-GAL, Defective GALK1 causes GALCT2, and Defective GALM causes GALAC4 pathways.
GALK1 is classified as a druggable target (Druggable Genome, Enzyme, and Kinase categories) with score 1.1.
Genetic testing for GALK1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
6 publications have been identified in PubMed for galactokinase deficiency. Research spans Review / Meta-Analysis (33%), Epidemiology / Natural History (33%), and Other (17%).
Ramani PK (2026). [PMID: 32809518](https://pubmed.ncbi.nlm.nih.gov/32809518/). *Unknown Journal*. [Other]
Rubio-Gozalbo ME (2025). [PMID: 39953772](https://pubmed.ncbi.nlm.nih.gov/39953772/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Garrett OS (2025). [PMID: 39143820](https://pubmed.ncbi.nlm.nih.gov/39143820/). *J Inherit Metab Dis*. [Epidemiology / Natural History]
Wada Y (2025). [PMID: 41398038](https://pubmed.ncbi.nlm.nih.gov/41398038/). *J Hum Genet*. [Review / Meta-Analysis]
Mangini L (2024). [PMID: 38974607](https://pubmed.ncbi.nlm.nih.gov/38974607/). *JIMD Rep*. [Basic Science / Preclinical]
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 4:04 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Prolonged neonatal jaundice |
Pregnancy and birth | 1 | Prolonged neonatal jaundice |